Analysts Set Glaukos Co. (NYSE:GKOS) PT at $129.82

Shares of Glaukos Co. (NYSE:GKOS) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $130.45.

Several equities analysts have recently issued reports on GKOS shares. Morgan Stanley boosted their price target on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Piper Sandler upped their target price on shares of Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Citigroup cut Glaukos from a “buy” rating to a “neutral” rating and lifted their price target for the company from $130.00 to $132.00 in a report on Wednesday, July 10th. Needham & Company LLC boosted their price objective on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Company raised their target price on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st.

Glaukos Stock Performance

Shares of GKOS opened at $129.11 on Friday. The stock has a market capitalization of $6.50 billion, a PE ratio of -44.83 and a beta of 1.02. The business’s fifty day moving average price is $127.91 and its 200 day moving average price is $116.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. Glaukos has a 12-month low of $59.22 and a 12-month high of $136.60.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). The company had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The business’s revenue was up 19.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.55) earnings per share. Equities research analysts forecast that Glaukos will post -2.18 EPS for the current year.

Insider Transactions at Glaukos

In related news, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the transaction, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,250 shares of company stock valued at $4,825,873. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Glaukos

Institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. purchased a new position in shares of Glaukos in the second quarter worth approximately $6,832,000. Natixis purchased a new position in Glaukos during the 1st quarter worth approximately $614,000. Vanguard Group Inc. raised its stake in Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock valued at $500,576,000 after purchasing an additional 72,159 shares during the period. Nomura Holdings Inc. lifted its holdings in shares of Glaukos by 3.2% in the fourth quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier’s stock valued at $18,444,000 after purchasing an additional 7,146 shares in the last quarter. Finally, UniSuper Management Pty Ltd purchased a new stake in shares of Glaukos in the first quarter valued at $913,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.